Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
In millions, except per share items | Nov-03-18 | Aug-04-18 | May-05-18 | Feb-03-18 | Oct-28-17 | Jul-29-17 | Apr-29-17 | Jan-28-17 |
| 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
Revenues: |
Merchandise sales | 2,069 | 2,428 | 2,212 | 3,589 | 2,810 | 3,414 | 3,329 | 5,125 |
Hardlines | 1,171 | 1,438 | 1,260 | 1,811 | 1,541 | 1,947 | 1,794 | 2,621 |
Apparel and Soft Home | 632 | 707 | 661 | 1,341 | 847 | 973 | 982 | 1,758 |
Food and Drug | 266 | 283 | 291 | 437 | 422 | 494 | 553 | 746 |
Total revenues [+] | 2,742 | 3,182 | 2,891 | 4,376 | 3,575 | 4,278 | 4,199 | 6,052 |
Products | | | 2,212 | 3,589 | | | 3,329 | 5,125 |
Services | | | 679 | 787 | | | 870 | 927 |
Revenue growth [+] | -23.3% | -25.6% | -31.2% | -27.7% | -28.9% | -24.5% | -22.2% | -17.1% |
Merchandise sales | -26.4% | -28.9% | -33.6% | -30.0% | -30.8% | -26.5% | | |
Hardlines | -24.0% | -26.1% | -29.8% | -30.9% | -28.2% | -23.2% | -20.9% | -17.1% |
Apparel and Soft Home | -25.4% | -27.3% | -32.7% | -23.7% | -28.1% | -26.8% | -24.5% | -18.2% |
Food and Drug | -37.0% | -42.7% | -47.4% | -41.4% | -42.7% | -36.9% | -33.7% | -24.6% |
Unit growth | -30.6% | -30.7% | | -29.9% | | | | -14.5% |
Cost of goods sold [+] | 2,327 | 2,494 | 2,302 | 3,470 | 2,891 | 3,328 | 3,290 | 4,789 |
Cost of product sales | | | 1,899 | 3,029 | | | 2,779 | 4,256 |
Cost of services | | | 387 | 423 | | | 489 | 509 |
Lease costs | 12 | 14 | 16 | 18 | 20 | 22 | 22 | 24 |
Gross profit | 415 | 688 | 589 | 906 | 684 | 950 | 909 | 1,263 |
Gross margin | 15.1% | 21.6% | 20.4% | 20.7% | 19.1% | 22.2% | 21.6% | 20.9% |
Selling, general and administrative [+] | 856 | 864 | 906 | 1,156 | 1,091 | 1,123 | 1,221 | 1,579 |
General and administrative | | | | 1,156 | | | | 1,579 |
Other operating expenses | -241 | -88 | -96 | -168 | -154 | -158 | -104 | -239 |
EBITDA [+] | -200 | -88 | -221 | -82 | -253 | -15 | -208 | -77 |
EBITDA growth | -20.9% | 486.7% | 6.3% | 6.5% | -45.7% | -93.8% | -11.5% | -60.3% |
EBITDA margin | -7.3% | -2.8% | -7.6% | -1.9% | -7.1% | -0.4% | -5.0% | -1.3% |
Depreciation and amortization | 65 | 66 | 67 | 73 | 89 | 83 | 87 | 97 |
EBIT [+] | -265 | -154 | -288 | -155 | -342 | -98 | -295 | -174 |
EBIT growth | -22.5% | 57.1% | -2.4% | -10.9% | -38.6% | -70.6% | -10.6% | -39.2% |
EBIT margin | -9.7% | -4.8% | -10.0% | -3.5% | -9.6% | -2.3% | -7.0% | -2.9% |
Non-recurring items [+] | 389 | 48 | -71 | 52 | -173 | -239 | -644 | 543 |
Asset impairment | 236 | 77 | 14 | 113 | 9 | 5 | 15 | 409 |
Loss (gain) on sale of assets | -76 | -103 | -165 | -211 | -316 | -380 | -741 | -81 |
Interest expense, net [+] | 168 | 186 | 165 | 150 | 136 | 111 | 126 | 114 |
Interest expense | 178 | 188 | 166 | 152 | 136 | 123 | 128 | 115 |
Interest income | 10 | 2 | 1 | 2 | | 12 | 2 | 1 |
Other income (expense), net [+] | -168 | -139 | -33 | | -248 | -270 | -50 | 11 |
Reorganization items | -131 | | | | | | | |
Other | -37 | -139 | -33 | | -248 | -246 | -46 | |
Pre-tax income | -990 | -527 | -415 | -357 | -553 | -240 | 173 | -820 |
Income taxes | -40 | -19 | 9 | -539 | 3 | 10 | -72 | -213 |
Tax rate | 4.0% | 3.6% | | 151.0% | | | | 26.0% |
Net income | -950 | -508 | -424 | 182 | -556 | -250 | 245 | -607 |
Net margin | -34.6% | -16.0% | -14.7% | 4.2% | -15.6% | -5.8% | 5.8% | -10.0% |
|
Basic EPS [+] | ($8.72) | ($4.68) | ($3.93) | $1.69 | ($5.17) | ($2.33) | $2.29 | ($5.68) |
Growth | 68.5% | 101.0% | -271.8% | -129.8% | -26.0% | -36.9% | -151.8% | 4.4% |
Diluted EPS [+] | ($8.72) | ($4.68) | ($3.93) | $1.69 | ($5.17) | ($2.33) | $2.29 | ($5.68) |
Growth | 68.5% | 101.0% | -271.8% | -129.8% | -26.0% | -36.9% | -151.8% | 4.4% |
|
Shares outstanding (basic) [+] | 109 | 109 | 108 | 107 | 108 | 107 | 107 | 107 |
Growth | 1.4% | 1.1% | 0.7% | 0.5% | 0.5% | 0.4% | 0.4% | 0.3% |
Shares outstanding (diluted) [+] | 109 | 109 | 108 | 107 | 108 | 107 | 107 | 107 |
Growth | 1.4% | 1.1% | 0.7% | 0.5% | 0.5% | 0.4% | 0.4% | 0.3% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|